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Abstract 
Since 1993, when the first small non-coding RNA was identified, our knowledge about 
microRNAs has been exponentially growing.  In this review we intend to focus on the main 
progresses on this field and to discuss the most important findings under a historical perspective. 
In addition, we examine microRNAs as disease diagnosis and prognosis markers as well as new 
therapeutic targets. 
 
Introduction 
microRNAs (miRNAs) are small non-coding RNAs (ncRNAs) with approximately 20 
nucleotides (nt) length that regulate gene expression posttranscriptionally by binding to 
3’untranslated regions (UTR), coding sequences or 5´UTR of target messenger RNAs (mRNAs) 
and leading to inhibition of translation or mRNA degradation [1,2,3]. It is predicted that 
miRNAs regulate approximately 30% of the human protein-coding genome [1]. miRNAs control 
the expression of genes involved in several biologic processes such as apoptosis, proliferation, 
differentiation and  metastasis [1,2,3]. 
Two decades ago, the existence and importance of miRNAs was completely unknown. 
Until then, the scientific community was focused on genes that codify for protein. The classical 
dogma that DNA is transcribed into RNA which then is translated into protein put aside the study 
of all the non-protein coding sequences. Only in 1993 the importance of miRNAs started to be 
revealed [4,5]. This review intends to highlight the pioneer studies that contributed to the brief 
history of miRNAs (Figure 1). 
 
Discovery of the first miRNA: lin-4 
Lin-4 was the first miRNA to be discovered, in 1993, by the joint efforts of Victor 
Ambros’s and Gary Ruvkun’s laboratories [3,4]. In the nematode C.  elegans, heterochronic 
genes control temporal development pattern of all larval stages. One of these genes is lin-4, 
discovered by the isolation of a null mutation that causes a failure in temporal development [6,7]. 
Animals with lin-4 loss-of-function mutations are missing some adult structures, are unable of 
laying eggs and reiterate early development programs at inappropriate late larval stages. Lin-4 
activity is required for the transition from L1 to L2 stage of larval development [7,8]. In 1987, 
Fergunsson et al., at Hortitz’s lab, found that a suppressor mutation in the gene lin-14 was able to 
revert the null-lin-4 mutation phenotype [9]. In fact, null mutations in lin-14 gene caused an 
exactly opposite phenotype of the null-lin-4 mutations [8,9]. The interesting opposite phenotype 
between defects in lin-4 and lin-14 genes indicated that lin-4 could negatively regulate lin-14 [8]. 
In 1989, Ambros worked with Ruvkun, at Horvitz’s lab, to clone lin-14 gene [8,10]. At this time, 
the two colleagues followed two independent careers: Ambros focus his research on lin-4 gene 
and Ruvkun on the study lin-14 gene.  
Ambros, together with Rosalind Lee and Rhonda Feinbaum, found that a 700bp fragment 
could contain lin-4 gene but could not find the conventional start and stop codons.  Even so, they 
introduced mutations in the putative ORFs but lin-4 function remained unchanged. Therefore, 
Ambros concluded that lin-4 did not encode a protein [4,8]. In addition, they found two very 
small lin-4 transcripts with only 61 and 22 nt length [4]. On the other hand, Ruvkun and his 
colleagues Bruce Wightman and IIho Ha, found that lin-14 was downregulated at a 
posttranscriptional level and that lin-14 3´UTR region was sufficient for the temporal regulation 
[5]. The two groups shared their unpublished data and in June 1992 Ambros and Ruvnkun 
independently came to the same conclusion: lin-4 transcripts were complementary to a repeated 
sequence in the 3´UTR of lin-14 gene [4,5,8]. In December 1993, in the same issue of Cell, 
Ambros and Ruvkun independently reported that the small and non-protein coding transcript lin-
4 regulates lin-14 through its 3’ UTR region [4,5,8]. A new unexpected cellular regulatory 
mechanism involving a non-protein coding transcript had been found! 
 
Discovery of a second microRNA: Let-7 
Likewise lin-4, let-7 is a heterochronic gene of C. elegans and was the second miRNA to 
be discovered, in 2000, seven years after the finding of the first miRNA. Reinhart, Slack et al. at 
Ruvkun's lab reported that let-7 was a 21 nt RNA controlling L4-to-adult transition of larval 
development [11]. Loss of let-7 activity causes reappearance of larval cell fates during adult 
stage of development, while increased let-7 activity causes precocious expression of adult fates 
[11]. Remarkably, the authors found that the retarded let-7 phenotype could partially suppress 
lin-41 (a let-7 target) loss-of-function mutations [11]. In fact, let-7 is complementary to two 
closely spaced sites in lin-41 3´UTR. Deletion of the lin-41 3’UTR region and let-7 mutations 
abolishes lin-41 downregulation, showing that both partners are necessary for this mechanism 
[11,12,13].  
Let-7 controls late temporal transitions during development across animal phylogeny. 
Unlike lin-4, let-7 sequence is conserved across species from flies to humans [14], which had a 
major impact on the study of this specific miRNA in other organisms [15,16].  let-7 RNA was 
detected in vertebrate, ascidian, hemichordate, mollusc, annelid and arthropod, but not in RNAs 
from plant and unicellular organisms [14,16]. In humans, it was detected at different expression 
levels in the majority of the tissues, including brain, heart, kidney, liver, lung, trachea, colon, 
small intestine, spleen, stomach and thymus [14]. Let-7 miRNA family refers to miRNAs that 
share complete sequence identity with let-7 at the 5’ ends, termed seed regions, and therefore can 
regulate the same targets [15]. Let-7 family within humans comprises 12 miRNAs. Some 
members of let-7 family identified and functionally analysed in C. elegans were mir-48, mir-84, 
and mir-241 [17-19]. These miRNAs act redundantly to control the L2-to-L3 transition, by 
repressing hbl-1 [19]. Nowadays, functional cooperation among miRNA family members 
continues to be studied [20].  
The discovery that let-7 is conserved across species triggered a revolution in the research 
of a new class of small ncRNAs, called miRNAs. Presently, thousands of miRNAs had been 
identified in humans and other species, and miRNA online sequences repositories, such as the 
miRbase database, are available [21,22,23]. Also, current tools and software developed for 
miRNA target prediction facilitate studies of miRNAs functional network [24,25]. 
 
miRNA biogenesis pathway and miRNAs function 
miRNAs are encoded in the genome as long primary transcripts (named pri-miRNAs) 
that contain a cap structure at the 5’ end and are poly-adenylated at the 3’ end. Pri-miRNAs are 
processed by the cellular RNaseII enconucleaseIII Drosha, together with DGCR8/Pasha proteins, 
into a structure of 60-110 nt, called precursor-miRNA (pre-miRNA), which is then exported 
from the nucleus to the cytoplasm by an Exportin-5 dependent mechanism. In the cytoplasm, the 
pre-miRNA is cleft by the RNaseIII enzyme Dicer-1, together with TRBP/PACT proteins, 
producing a short imperfect double-stranded miRNA duplex. This duplex is then unwound by an 
helicase into a mature miRNA with approximately 20 nt length, which is then incorporate in a 
multicomponent complex constituted by Argonaute family protein members known as RISC 
[26]. 
 In a historical perspective, the knowlegment acquired from RNAi was determinant for 
understanding miRNAs processment and activity. In  2000, Zamore et al. studied RNAi  process 
and described that double-stranded RNA fragments of 21-23 nucleotides were targeting the 
mRNA cleavage [27]. The functional unit of RNAi was therefore the same size as miRNAs. In 
2001, two reports were crucial for elucidation of the miRNA biogenesis mechanism, as both 
reports suggest an involvement of RNAi pathway components in miRNAs maturation [28,29]. 
Grishok and colleagues showed that a homolog of Drosophila Dicer (dcr-1), and two homologs 
of rde-1 (alg-1 and alg-2) were essential for lin-4 and let-7 activity. Inactivation of these genes 
caused phenotypes similar to lin-4 and let-7 mutations [28]. Simultaneously, Hutvagner et al. 
described that let-7 pre-miRNA is cleaved by Dicer. In fact, when cells were transfected with 
siRNA duplex corresponding to human Dicer enzyme, pre-let-7 accumulated into the cells [29]. 
Taken together, these two papers corroborate the intersection between RNAi and miRNA 
pathway and opened the door for understanding the formation of mature miRNAs. 
In the miRNAs biogenesis pathway, Drosha and Dicer are spatially separated, being 
localized in the nucleus and in the cytoplasm, respectively. In 2004, Lund et al. reported that 
Exportin-5 was the key player mediating the efficient nuclear export of the short miRNA 
precursors [30].  However some miRNAs such as miR-29b are predominantly located in the 
nucleus [31]. In 2007, Hwang et al. found that some miRNAs contain additional sequences 
elements that control their subcellular localization. In fact, miR-29b possesses a hexanucleotide 
terminal motif that directs its import into the nucleus. The authors show that, despite their small 
size, miRNAs can contain additional cis-acting regulatory motifs that might influence their 
posttranscriptional behavior and concluded that miRNAs with common 5’ ends, predicted to 
regulate the same targets, might have distinct functions [31]. 
 miRNAs’ main function is to inhibit protein synthesis of protein-coding genes, either by  
inhibition of translation or mRNA degradation. However, the relative contribution of each 
mechanism to repression was unknown until recently. In an elegant study, Guo et al. used 
ribosome profiling to measure the overall effects on protein production and simultaneously 
measured effects on mRNA levels and concluded that inhibition of translation (no changes in 
mRNA levels of miRNA targets) had a modest influence on repressing protein levels whereas 
mRNA destabilization was the predominant miRNAs mechanism of action to decrease their 
targets levels [32].  
 Besides mRNAs repression, miRNAs have been also reported to activate translation of 
targeted mRNAs [33,34]. Vasudevan et al. were the first to clearly demonstrate that, in some 
instances, miRNAs can work as translational activators. Under serum starvation conditions, 
TNFα AU-rich elements recruited miR369-3 to mediate translation upregulation. However, in 
synchronized proliferating cells it caused translation repression. In addition, on cell cycle arrest, 
let-7 and the synthetic miRNA-cxcr4 induced translation whereas they repress translation in 
proliferating cells. Therefore, miRNAs can switch between translation repression and activation 
in coordination with cell cycle [34]. In 2008, Place et al. provided new evidence that miRNAs 
can induce gene expression and were the first to show that miRNAs can target genes promoters. 
The authors showed that miR-373 targets the promoter of E-cadherin and CSDC2 and induced 
their expression [35]. 
 For a long time, studies on miRNA-target interaction were confined to 3’UTR of 
mRNAs, probably because the first studies on miRNAs focused on this region. In 2007, Lytle et 
al. was the first to suggest that miRNAs could associate to any position of target mRNAs and 
demonstrated that mRNAs targets were efficiently repressed by miRNA-binding sites in 5’UTR 
[36]. In 2008, Tay et al. reported that binding sites in CDS are abundant and experimentally 
show that mouse Nanog, Oct4 and Sox2 genes have miRNA-binding sites in their CDS. MiRNAs 
targeting these genes modulate embryonic stem cell differentiation [37]. 
 In 2010, Eiring et al. reported a remarkably finding for our understanding on how 
miRNAs function. The authors found that, in addition to miRNAs gene silencing activity thought 
base pairing with mRNA targets, miRNAs also have decoy activity that interferes with the 
function of regulatory proteins [38]. Particularly, miR-328 binds to hnRNP E2 independently of 
the miRNA’s seed region and prevents its interaction with CEBPA mRNA [38]. In conclusion, 
the authors introduced the new concept that miRNAs can work as molecular decoys for RNA-
binding proteins [38]. 
 
microRNAs in disease: an historical perspective 
microRNAs in Cancer 
The first report suggesting a role of miRNAs in cancer was published in 2002 [38]. MiR-
15 and miR-16 were found to be located at chromosome 13q14, a region frequently deleted in 
chronic lymphocytic leukemia (CLL). Calin et al. discovered that either genes are deleted or 
downregulated in over 60% of B-cell human CLL, indicating that these genes behave as tumor 
suppressors in CLL [39]. Consequently, the same group identified that a significant percentage 
of miRNAs is located at fragile sites and in regions altered in cancers, including regions of 
amplification or loss of heterozygosity or breakpoints, suggesting that miRNAs as a new class of 
genes had a relevant role of in human cancer pathogenesis [40]. 
  Oligonucleotide miRNA microarrays and, more recently, deep sequencing (next 
generation sequencing) has permitted the analysis of the entire known miRNAome. In addition, 
other methods such as bead-flow cytometry, quantitative real-time polymerase chain reaction and 
high-throughput array-based Klenow enzyme assay, have been used to assess miRNA expression 
in tumors and other diseases. To date, altered miRNA expression had been reported in almost all 
types of cancer [41].  
In 2005, the first reports addressing the biological function of miRNAs in cancer were 
published. MicroRNAs can act as oncogenes (oncomirs) or tumor suppressors and are involved 
in a variety of pathways deregulated in cancer [42]. In March 2005, Johnson et al. reported the 
first miR-target interaction with relevance to cancer. The authors demonstrate that in C. elegans 
let-7 targets let-60, encoding the C. elegans ortholog of human oncogene RAS. In addition, they 
show that human RAS expression is regulated by let-7 in cell culture. Accordingly, let-7 
expression is decreased in lung cancer comparing to normal tissue and it correlates with the 
increased RAS proteins levels detected in lung tumor samples [43]. Cimmino et al. reported that 
miR-15 and miR-16, the first two miRNAs associated to cancer, played a role in apoptosis 
regulation by targeting the anti-apoptotic BCL2 mRNA [44]. Also in 2005, He et al. studied for 
the first time the contribution of miRNAs for tumor development in vivo. By overexpressing 
miR-17-22 cluster, which is upregulated in human lymphoma, the authors were able to accelerate 
lymphomagenesis in a mouse B-cell lymphoma model carrying c-myc oncogene [45]. 
Furthermore, O’Donnell et al. reported for the first time that a transcription factor, specifically 
MYC, modulated the expression of the same cluster of miRNAs and consequently the E2F1 
expression [46]. From 2005 until present, hundreds of scientific communications have been 
reporting on the role of miRNAs in tumors, as well as the regulation of miRNAs by other 
transcription factors such as TP53 (for a detailed review see [47]). In 2010 Medina et al., 
reported the results on mice that conditionally overexpressed miR-21 and this clearly 
demonstrate that overexpression of a single miRNA, specifically miR-21, was sufficient to cause 
tumors development. In addition, the authors proved that tumor volume and survival were 
dependent on miR-21 overexpression and that tumor regresses when miR-21 was inactivated, 
proving for a first time an oncogenic miRNA addiction for tumor cells [48].   
MicroRNAs deregulation can be caused by several mechanisms including deletion, 
amplification, mutation or dysregulation of transcription factors that target specific miRNAs. In 
addition, miRNAs can be controlled by epigenetic mechanisms. In 2006, Saito et al. was the first 
to demonstrate that miRNAs expression could be controlled by the two major epigenetic 
mechanisms: DNA methylation and histone modifications [49,50]. When Saito et al. 
simultaneously treated a human bladder carcinoma cell line with 5-aza-2-deoxycytidine (a DNA 
methylation inhibitor) and 4-phenylbutyric acid (a histone deacetylase inhibitor), 17 out of 313 
human miRNAs were found upregulated. In particular, miR-127 was upregulated after treatment 
with these drugs and expression of one of its targets, BCL6, was suppressed [49]. Accordingly, 
miR-127 expression was downregulated in primary human bladder and prostate tumors 
comparing to normal tissue [49]. Therefore, the authors concluded that in cancer tissue miR-127 
is subject to epigenetic silencing [49,50]. This finding opened the field of epigenetics to miRNAs 
regulation. Interestingly, a bidirectional connection between epigenetic and miRNAs has been 
established. On one hand, epigenetic mechanisms control miRNAs and, on the other hand, 
miRNAs can target essential epigenetic key players. One of the first reports suggesting 
methylation could be controlled by miRNAs was described in 2004 in Arabidopsis - Bao et al. 
suggests that miR-165 and miR-166 are required for the methylation at the PHB gene [50,51]. 
In cancer patients, metastasis is the principal cause of death. Metastatic process involves 
multiple steps: cell motility, invasion of adjacent stroma, intravasation, systemic dissemination 
(either though the blood or lymph), extravasation into the parenchyma of distant tissues and 
finally proliferation at a new site giving rise to secondary tumor. In this process miRNAs have a 
dual role as they can promote or inhibit metastasis [52]. The first sighting about miRNA function 
as metastasis activators was reported by Ma et al [53]. MiR-10b positively regulates cell 
migration and invasion in vitro and is capable of initiating tumor invasion and metastasis in vivo. 
MiR-10b acts by directly targeting HOXD10 which is a transcriptional repressor of RHOC, a key 
player in metastasis. Concordantly, miR-10b expression is elevated in about 50% of metastatic 
breast tumors compared with metastasis-free tumors or normal breast tissues [53]. On the same 
line, Huang et al. found that human miR-373 and miR-520c stimulated by suppression of CD44 
cancer cell migration and invasion in vitro and in vivo [54]. 
In contrast, miRNAs can prevent tumor metastasis. Tavazoie et al. published the initial 
study of miRNAs as metastasis suppressors [55]. In breast cancer, patients with low expression 
levels of miR-335, miR-126 and miR-206 had a shorter median time to metastatic relapse. 
Restoration of their expression in breast cancer cell lines decreased number of metastasis in 
inoculated mice. These miRNAs have distinct mechanisms for metastasis suppression: 
restoration of miR-126 expression significantly suppressed overall tumor growth; while 
restoration of miR-335 or miR-206 levels altered cells morphology, possibly causing a decrease 
in cell motility [55]. 
It was not therefore surprising that Lujambio et al. reported in 2008 that DNA 
methylation-associated silencing of tumor suppressor miRNAs contributes to the development of 
human cancer metastasis and that the reintroduction of miR-148a and miR-34b/c in cancer cells 
with epigenetic inactivation inhibited their motility, reduced tumor growth, and inhibited 
metastasis formation in xenograft models, with an associated down-regulation of the miRNA 
oncogenic target genes, such as C-MYC, E2F3, CDK6, and TGIF2 [56]. 
 
microRNAs in cardiovascular diseases                                                        
In 2005, Zhao et al. reported that miR-1-1 and miR-1-2 were specifically expressed in 
cardiac and skeletal muscle precursor cells and that miR-1 regulates ventricular cardiomyocytes. 
MiR-1 overexpression specifically in the developing heart of mouse model leads to a decrease 
pool of proliferating ventricular cardiomyocytes [57]. In the same year, Kwon et al. found that 
miR-1 in Drosophila modulates cardiogenesis [58]. Subsequently, in 2006, Cheng et al. reported 
that miRNA-1 promotes myogenesis, while miR-133, clustered together with miR-1 on mouse 
chromosome 2, stimulates myoblast proliferation [59]. Theses three reports were the first to 
suggest a possible involvement of miRNAs in cardiac-related human diseases. Rooij et al. 
published the first report associating miRNAs to heart failure and cardiac hypertrophy [60], 
which occurs in response to stress and injury and is characterized by an increase in 
cardiomyocyte size with no change in myocyte number [61]. Using miRNA microarray analysis, 
more than 12 miRNAs were identified as deregulated during cardiac hypertrophy and heart 
failure [60]. Interestingly, overexpression of miR-195 led to heart failure on mouse model and to 
hypertrophic growth of cultured rat cardiomyocytes [60,61]. In the subsequent years, several 
studies demonstrated miRNA aberrant patterns in cardiac hypertrophy and analyzed their roles 
[61], including miR-21, which is also one of the most deregulated miRNAs in cancer [62,63], 
suggesting common miRNA pathways involved in both abnormal states. 
 
microRNAs in autoimmune diseases 
Psoriasis is the most prevalent chronic inflammatory skin disease in adults and the first 
inflammatory disease in which miRNAs were implicated [64]. In 2007, Sonkoly et al. described 
that miR-203, exclusively expressed in keratinocytes, is upregulated in psoriasis-affected skin 
compared with healthy human skin or another chronic inflammatory skin disease. Interestingly, 
miR-203 targets SOCS-3 [64]. It has previously been described that SOCS-3 suppression leads to 
sustained activation of STAT3 in response to IL-6 and that STAT3 constitutively activation in 
keratinocytes leads to spontaneous development of psoriasis in mice [64-66]. MiR-146 is the 
other miRNA Sonloky et al. found associated with psoriasis. It was found upregulated in 
psoriasis patients and it is absent from keratinocytes and dermal fibroblasts but it is expressed by 
immune cells [64]. The upregulation of a miRNA associated with inflammation is not surprising 
since several studies support a role of a deregulated immune system in psoriasis [67]. MiR-146 
targets IRAK1 and TRAF6, both regulators of the TNF-alpha signaling pathway [68]. 
Treatments using anti-TNF agents, such as infliximab, etanercept or adalimumab are effective 
for psoriasis [69,70]. Therefore, future studies should address treatments with miR-203 and miR-
146 antagomirs for psoriasis patients in order to improve their quality of life [64]. 
Rheumatoid arthritis (RA) is a systemic autoimmune disorder characterized by chronic 
inflammation of synovial tissue [71]. In 2008, three studies reported the first association studies 
between RA and miRNAs. Stanczyk et al. described increased expression of miR-155 and miR-
146 in RA synovial fibroblasts and RA synovial tissue [72]; one month later, Nakasa et al. 
confirms the expression of miRNA-146 in RA synovial tissue and further describes its induction 
by stimulation with TNF and IL-1 [73]; and in the same year, Pauley et al. reported increased 
expression of miR-146 in rheumatoid arthritis peripheral blood mononuclear cells, which mimics 
the results found on synovial tissue/fibroblasts [74].  Taken together these results suggest that 
miR-146 can be used as a biomarker for RA. In addition, several other miRNAs have been 
implicated RA, such as, miR-155, miR-132, miR16 [75], miR-346 [76] or miR-223 [77].  
In lupus erythematosus (SLE), an autoimmune disorder characterized by excessive 
production of a variety of autoantibodies against several self-antigens [78], few studies have 
been published about the differently expressed miRNAs. Nonetheless, miRNAs might be 
implicated in etiology of this disease and evidences suggest that miRNAs are potential diagnostic 
markers in SLE [79-82]. Dai et al. described for the first time 16 miRNAs differently expressed 
in SLE [79]. The authors were also the first to describe 66 miRNAs differently expressed in 
lupus nephritis (LN) patients [83]. Several studies in 2010 confirm the link between miRNAs 
and SLE/LN. Two miRNAs (miR-21 and miR-148a) are overexpressed in CD4+ T cells from 
patients with lupus. MiR-148a directly downregulated DNMT1 expression and miR-21 indirectly 
downregulates DNMT1 expression by targeting, RASGRP1 an important autoimmune gene. By 
causing DNMT1 downregulation, both miRNAs contribute to DNA hypomethylation in lupus 
CD4+ T cells [80]. Te et al. analyzed miRNAs in lupus nephritis patients from two racial groups 
(African American and European American) and concluded that 5 miRNAs (miR-371-5P, miR-
423-5P, miR-638, miR-1224-3P and miR-663) were differentially expressed across different 
racial groups [81]. Recently, Zhao et al. showed that miR-125 expression was reduced and, 
accordingly, expression of its predicted target KLF13 was increased in SLE patients [82]. 
Although studies with larges number of samples are necessary, these studies implicate 
miRNAs in immune diseases pathogenesis and suggest that they can be used as potential 
diagnostic markers. 
 
microRNAs in neurodegenerative diseases 
A significant fraction of miRNAs is specifically expressed in the central nervous system 
and plays a role in neuronal development [84]. Consequently, it seems natural that miRNAs have 
been linked to neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s 
disease, which are caused by excessive neuronal death in the diseased brain [85]. In 2007, there 
were reported the first studies associating miRNAs to neurodegenerative diseases. Using 
Purkinje cells, Schaefer et al. suggested an involvement of miRNAs in neurodegenerative 
disorders by showing progressive neurodegeneration (cerebellar degeneration and development 
of ataxia) in the absence of the miRNA biogenesis key component, DICER, which consequently 
causes progressive loss of miRNAs [86,87]. Lukin et al. found that miR-9, miR-25b and miR-
128 were upregulated, and that miR-124a was dowregulated, in Alzheimer brain samples when 
compared with aged-match controls [88,89]. In the same year, a miRNA important for 
maturation and function of dopaminergic neurons, miR-133b, was one of the first miRNAs 
reported to be lost in Parkinson’s disease midbrain tissue [90].  
MiRNA expression profiles for neurodegenerative diseases are challenging for two main 
reasons: 1) some miRNAs are expressed specifically by only some brain regions or brain cell 
types; 2) unlike cancer, it is much more challenging to obtain disease-affected and healthy tissue 
from the same patient, which turns more difficult to control these type of studies [91]. From 2007 
till present, several studies have been linking miRNA modifications to regulation of proteins 
involved in these diseases [92]. Although studies seem to indicate that miRNAs can participate 
in neurodegenerative disease initiation or progression, more work is necessary to clarify if 
changes in miRNAs expression directly contribute to the pathogenesis of neurodegenerative 
diseases or if they are secondary events caused by deregulated pathways in these diseases [89]. It 
is predicted that in the next years, increase publications on miRNAs will let to novel insight in 
this field [91]. 
 
microRNAs as molecular biomarkers 
In a clinical context, miRNAs can be extremely useful as disease diagnosis, prognosis 
and prediction of therapeutic response markers. In 2004, Takamizawa and coworkers were the 
first to pinpoint the prognostic value of miRNAs by showing that let-7 expression was reduced in 
lung cancers and that lung cancer patients presenting low let-7 expression levels have a 
significantly shorter survival after potentially curative resection [93]. In 2005, Calin et al. 
reported the first study showing the diagnostic/prognostic importance of miRNAs at a 
genomewide level [94]. The authors found that miRNA expression profiles could be used to 
distinguish normal B cells from malignant B cells in patients with CLL. In fact, a unique miRNA 
expression signature is associated with prognostic factors such as ZAP-70 expression (predictor 
of early disease progression) and mutational status of IgVh. In addition, the authors found 9 
miRNAs differently expressed between patients with a short interval from diagnosis to initial 
therapy and patients with a significantly longer interval. Furthermore, this study also highlight 
that one mechanism of miRNA deregulation is mutation: a germline mutation in the precursor of 
miR-16-1-miR15a caused low levels of miRNA expression both in vitro and in vivo [94]. 
Currently, the clinical utility of miRNAs as diagnostic/prognostic biomarkers has been 
demonstrated in several types of cancer by numerous studies using tumor samples removed 
during surgery or biopsies [42]. However, for non-malignant diseases larger and more studies 
should be conducted.  
 
microRNAs as biomarkers in plasma or serum 
Current techniques for cancer diagnosis commonly involve a biopsy to the cancer tissue. 
Because this technique is invasive and unpleasant for patients, some studies have been focused 
on the search for biomarkers in human fluids such as plasma/serum, urine or saliva. Blood 
samples from patients are usually readily available and many biological molecules, as circulating 
nucleic acids, can be found in blood serum/plasma, including miRNAs [95,96]. These small non-
coding RNAs in the blood are incorporated in microparticles and exosomes (50- to 90-nm 
membrane vesicles) that prevent its degradation, conferring an advantage to the use of miRNAs 
as markers in serum [95]. In addition, detection of miRNAs is serum is easy due to highly 
sensitive PCR detection methods, the lack of post-processing modifications of miRNAs, and 
simple methods of miRNAs extraction from serum [95]. The first report addressing the utility of 
miRNAs as diagnostic tools in biological fluids was published in 2008 by Chim et al. in a study 
that detected placental miRNAs in the maternal plasma [97]. In the same year, Lawrie et al. [98], 
by comparing serum from diffuse large B-cell lymphoma patients and healthy controls, found 
that miR-155, miR-210 and miR-21 levels were significantly upregulated in patients. 
Interestingly, these miRNAs have been shown to be deregulated in tumors. Moreover, high 
expression of miR-21 in patients serum was correlated with improved relapse-free survival times 
[98]. To date, miRNAs deregulation in serum of cancer patients have been described in several 
tumors as leukemia, lymphoma, gastric, colorectal, lung, oral and squamous cell cancer, breast, 
ovarian, prostate, pancreatic and hepatocellular cancer [96].  
Furthermore, a recent report analyzed miRNAs plasma levels in rheumatoid arthritis or 
osteoarthritis patients. Remarkably, plasma miR-132 was significantly higher in healthy controls 
than in rheumatoid arthritis or osteoarthritis patients and therefore it can be a potential diagnostic 
marker. In addition, plasma miRNA levels correlate with disease activity in rheumatoid arthritis. 
However, miRNAs included in this study failed to differentiate rheumatoid arthritis and 
osteoarthritis. Thus, others miRNAs specific for both diseases should be studied. Interestingly, 
this study also analyzes miRNAs present in another body fluid, namely in synovial fluid, and 
demonstrate that miRNAs from plasma and from synovial fluid have different origins [99,100].  
In order to translate miRNAs expression serum evaluation into a clinical routine for 
diagnostic/prognosis practice, it is still necessary to standardize the methodologies used for these 
studies, namely, serum/plasma extraction procedures and storage conditions, housekeeping 
miRNAs for normalization in serum samples or the used of same statistical methods for data 
analysis [95]. In addition, large studies reporting miRNA levels in plasma and serum with 
detailed clinical data information, together with normal controls from both genders and different 
ages are still missing [96].  
 
Therapeutic implications 
MiRNAs are aberrantly expressed in several diseases; therefore, it is not surprising that 
these small ncRNAs represent potential therapeutic targets for the diseases they are functionally 
associated with. MiRNAs that are upregulated in diseases should be targeted using anti-miRNAs 
which are antisense oligonucleotides with specific modifications [101]. For instance, antagomirs, 
a class of anti-miRNAs that is cholesterol-conjugated to facilitate cellular intake and serum 
proteins binding, could be used to block oncomirs effect in cancer [101,102]. In 2004, Hutvagner 
et al. successfully copy the phenotype of let-7 loss-of-function mutation by injecting a 2’ O-
methyl oligonucleotide complementary to let-7 miRNA into C. elegans larvae [103]. In 2005, 
Krutzfeldt et al. reports for the first time the use of antagomirs in vivo in mammalians [104]. In 
mouse model, Krutzfeldt and colleagues systemically deliver via intravenous injection 
antagomirs against miR-16, miR-122, miR-192 and miR-194 which specifically downregulated 
the corresponding miRNAs. Silencing of miRNAs using antoagomirs was long lasting and miR-
16-antagomir effects were detected in multiple tissues, except in brain, possibly due to the blood-
brain barrier [101,102,104,105]. Other approaches to efficiently inhibit miRNAs in vivo is the 
use of locked nucleic acid (LNA) oligos or 2’-O-methoxyethyl phosphorothioate (MOE) 
modification [102]. Elmen et al. evaluated for the first time the effect of an LNA-antimiR in non-
human primates with surprising results. The authors intravenous injected a LNA-anti-miRNA-
122 into African green moneys and were able efficiently silence the mature miR-122. The effect 
was long-lasting and safe, as toxicity associated to LNA as well as histopathological changes 
were not detected [106]. Two years later, Landford et al. described the utility of anti-microRNAs 
for the clinical pratice. MiR-122 is a liver-expressed miRNA essential for hepatitis C virus 
replication (HCV). Using a LNA-anti-miR-122, the authors were able to suppress HCV viremia 
in chronically HCV-infected chimpanzees. Moreover, this therapy generated a high barrier to 
resistance and no side effects were detected [107].  
In addition to theses direct-inhibitory methodologies, an indirect technology can be used 
through downregulation of miRNA biogenesis pathway components. Tetracycline-inducible 
shRNAs could be used to downregulate Dicer or Drosha, key components of the miRNA-
biogenesis pathway; however, this mechanism should be tightly controlled as downregulation of 
this pathway will have an effect on all miRNAs [101,102].   
On the other hand, when miRNAs downregulation promotes disease, as it is the case of 
some miRNAs dowregulated in tumors which function as tumor suppressors, a therapeutic 
approach would be to restore the mature miRNA levels in the proper tissue/cells. In this 
situation, it should be used synthetic RNA duplexes, resembling siRNA molecules, that will 
mimics miRNAs duplex and will be recognized by RISC complex [102]. This complex will 
process it as the endogenous miRNA, by loading the stand with the sequence identical to the 
mature miRNA. This approach still needs to be evaluated in vivo since some challenges, such as 
stability and delivery strategies, need to be improved [101,102,108]. The use of short-hairpins 
driven by Pol III promoters could be a strategy for re-expression of miRNAs in the cells [108]. 
Though, dosage used in this mechanism has to be narrowly controlled, since sustained shRNA 
high-level expression in livers of adult mice has shown to be fatal [109].  In 2009, Kota et al. 
demonstrated how useful systemic administration of miRNAs can be for anti-cancer therapy. 
MiR-26a is expressed at low levels in hepatocellular carcinoma but normally expressed in other 
tissues. The authors used an adeno-associated virus to mediate miR-26a delivery in a mouse 
model of liver cancer and were able to reduce cancer cell proliferation and induce tumor cells 
apoptosis, which consequently caused tumor regression. Since only cancer cells present miR-26a 
downregulation, the delivery was highly specific and didn’t affect the normal tissue that was 
tolerant to miR-26a restoring [110]. 
 
Concluding remarks 
MiRNAs were discovered in 1993 and rapidly became an exciting topic of research 
during the last decade with the number of publications growing exponentially. Like miRNAs, 
other ncRNAs have recently been linked to diseases [111, 112]. Therefore, we may predict that 
advances on understanding the roles of other classes of ncRNA-mediated regulation in diseases 
will be revealed at an extremely rapid rate in next years. In future years, it is expected that the 
acquired biological knowledge on miRNAs can be widely translated into the clinics. Despite 
major challenges that still need to be overcome (such as tissue specific delivery) miRNAs hold a 
great potential as therapeutic targets.  
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Figure 1 – Historical perspective on the evolution of our knowledge about miRNAs. miR: 
microRNA; UTR: untranslated regions; CDS: coding sequences; LNA: locked nucleic acid 
 
  
 
